Navigation Links
VaxInnate to discuss seasonal and pandemic flu vaccines during BIO 2008 this week
Date:6/15/2008

SAN DIEGO, CA, June 16, 2008 -- VaxInnate Corporation announced today that it will discuss its novel proprietary technology for producing seasonal and pandemic influenza vaccines during BIO 2008 here this week.

VaxInnate will participate in the following three BIO 2008 panel discussions:

On Tuesday, June 17th

  • "Influenza Research and Surveillance: Preparing for the Next Pandemic,"
    8:15-9:45 am in Room 29A including Robert Becker, PhD, MBA, VaxInnate's Vice President of Business Development

On Thursday, June 19th

  • "Vaccine Renaissance,"
    8:30-10:00 am, Room 29A including Dr. Robert Becker

  • "Moore's Law for Biomanufacturing: Innovation in a Maturing Biologicals Industry,"
    4:00 - 5:30 pm, Room 29B including Edward Arcuri, PhD, VaxInnate's Chief of Operations (COO)

VaxInnate's Approach

VaxInnate's novel technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of influenza vaccines.

VaxInnate's approach to developing and producing influenza vaccines is based upon a proprietary combination of toll-like receptor (TLR) mediated immune enhancement and recombinant bacterial production of vaccine antigen. This proprietary technology could significantly reduce the time required to produce supplies of influenza vaccine sufficient to meet national and even global needs.

VaxInnate's use of bacterial expression for production of influenza vaccines does not require costly expansion of manufacturing capacity, as do other influenza vaccine products. Due to its efficiency and transferability, VaxInnate's flu vaccine could instead be produced in existing biotechnology facilities that have microbial production capacity.

No other vaccine technology in use or in development today has these same potential capabilities.

Results of a Phase I study of VaxInnate's M2e universal vaccine candidate will be available this summer. The company plans to present the study data at a major scientific conference later this year and publish the data in a peer-reviewed journal.


'/>"/>

Contact: Janet Skidmore
skidmorecomm@earthlink.net
215-658-4915
VaxInnate
Source:Eurekalert

Related biology news :

1. Scientists, policymakers and industry leaders gather to discuss ocean iron fertilization
2. Book on weeds and invasive plants discusses how to manage them using ecological approaches
3. Presidents of Iceland, Bangladesh to discuss global climate change in New Orleans
4. Art meets science: Engineer discusses his photographs in free UH lecture
5. Leading researchers and experts gather to discuss latest advancements in drug discovery
6. Japanese and German researchers meet to discuss climate change
7. Biophysical Society to host discussions on the teaching of evolution and on the energy crisis
8. MIT professor to discuss future of biofuels
9. DHS, business leaders discuss technology to protect US at Homeland Security conference
10. Wildlife Conservation Society study finds seasonal seas save corals with tough love
11. NASA technology helps predict and prevent future pandemic outbreaks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... , Feb. 7, 2017 The ... largely by the confluence of organizations, desires to ... for knowledge-based systems (password and challenge questions), biometrics ... and government systems. The market is driven by ... demarcation between consumer and enterprise uses cases, with ...
(Date:2/7/2017)... , February 7, 2017 Ipsidy ... Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a ... transaction processing services, is pleased to announce the following ... Effective January 31, 2017, Philip D. ... Directors, CEO and President.  An experienced payment industry professional ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)...  VWR Corporation (NASDAQ: VWR), the leading global independent provider ... today reported its financial results for the fourth quarter and ... 4Q16 record quarterly net sales of $1.13 ... basis. 4Q16 EMEA-APAC segment net ... the Americas net sales increased 2.5%, or down 0.9% on ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 ... dollars, except per share data, unaudited)Three Months Ended December ... BioMarin Revenue $     ... 22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
Breaking Biology Technology: